Recombinant desulfatohirudin (HI), a potent and specific thrombin inhibitor, was compared with heparin (HE) as an adjunct to streptokinase thrombolysis. In pentobarbital-anesthetized dogs, an occlusive thrombus (whole blood+thrombin) was introduced into the left anterior descending coronary artery (LAD) with superimposed endothelial damage and distal high-grade stenosis. Intravenous infusion of saline (vehicle), HI (0.3 mg/kg followed by 0.3 mg/kg per hour, 1 mg/kg followed by 1 mg/kg per hour, or 2 mg/kg followed by 2 mg/kg per hour), or HE (60 units/kg followed by 40 units/kg per hour or 100 units/kg followed by 60 units/kg per hour) was initiated 15 minutes before streptokinase (750,000 units for 60 minutes) administration. Vessel patency was monitored for 180 minutes after streptokinase administration with a volume flow probe on the proximal LAD. In dogs treated with no adjunctive agent (saline control), none of the vessels were recanalized with streptokinase. Both HI and HE promoted reperfusion, inhibited reocclusion, and reduced the residual thrombus mass in a dose-dependent fashion. However, at comparable levels of therapeutic anticoagulation (activated partial thromboplastin time [APTI] = 1.5-2.0 times baseline) HI exhibited a higher incidence of reperfusion (eight of eight dogs [100%] versus one of eight dogs [12%J), a shorter time to reperfusion (33±6 versus 59 minutes), a longer duration of initial reperfusion (106±21 versus 10 minutes), and a smaller residual thrombus mass than did HE. Likewise, the slope of the relation between the APTT prolongation and the total reperfusion time ("anticoagulation/ antithrombosis profile") was almost five times higher for the combined HI data than for the HE data. Our results indicate that HI is more effective than HE in enhancing and sustaining coronary recanalization with streptokinase at a HI dose that modestly prolongs coagulation time and does not alter bleeding times. (Circulation Research 1993;72:1091-1102 
R esistance to coronary recanalization and clot lysis with subsequent acute thrombotic reocclusion continue to limit the effectiveness of thrombolytic therapy even in the presence of adjunctive antiplatelet and anticoagulant agents such as aspirin and heparin (HE). The antithrombotic efficacy of HE may be limited primarily because it is an indirect inhibitor of thrombin requiring antithrombin III but also because HE may be neutralized by substances released by platelets and may itself stimulate platelets.' For these reasons and because of the potent activation of platelets by thrombin, direct inhibitors of thrombin appear to exhibit a distinct antithrombotic advantage over the indirectly acting anticoagulant HE.
A naturally occurring, potent, and specific thrombin inhibitor was first isolated from the salivary glands of the 1092 Circulation Research Vol 72, No 5 May 1993 Materials and Methods
Animal Preparation
Experiments were conducted on colony-bred male mongrel dogs weighing [17] [18] [19] [20] [21] [22] [23] [24] kg (Barton's West End Farms, Oxford, N.J.). All potential experimental animals were screened for normal activated partial thromboplastin times (APTTs) and prothrombin times (PTs) while in the conscious state upon entry to our colony. Coagulation times were measured on 36 dogs to determine a normal range for our population. The resulting normal ranges for APTT and PT were 8.2-16.1 (12.16±3.92 [mean+2 SDI) seconds and 6.2-7.2 (6.72±0.52) seconds, respectively. Only dogs with APTTs and PTs within these respective ranges were used for the subsequent coronary thrombosis experiments. All animal studies and procedures were approved by the institutional animal care committee and conducted in accordance with the guidelines established in "Guide for the Care and Use of Laboratory Animals" (US Department of Health and Human Services publication No. [NIH] .
On the day of the thrombosis study, dogs were anesthetized with pentobarbital sodium (30 mg/kg i.v.). A stable plane of anesthesia was maintained throughout the experiment by administering supplemental doses of intravenous pentobarbital. Rectal temperature was monitored and controlled within ±0.5°C of baseline temperature with a thermal blanket and heat lamp.
After intubation with a cuffed endotracheal tube, the animals were ventilated with room air by means of a positive-pressure respirator (model 607, Harvard Apparatus, South Natick, Mass.). The volume was adjusted to 15 ml/kg body weight. A positive end-expiratory pressure of 5-7 cm water was applied to prevent atelectasis. Arterial blood gases and pH were measured frequently (model ABL-3, Radiometer America, Inc., Westlake, Ohio) and maintained within a physiological range (pH 7.35-7.45 ; Pco2, 30-40 mm Hg; Po2>80 mm Hg) by adjusting the respiration rate, administering sodium bicarbonate, and supplementing the inspired gas with 100% 02 as required.
Cannulas were inserted into a femoral vein for injection and infusion of drugs, pentobarbital, and bicarbonate. Systemic arterial pressure was measured with a pressure transducer (model P23XL, Gould Instruments, Cleveland, Ohio) and a catheter that was inserted into the aorta via a femoral artery. Mean arterial pressure was derived by electronic integration of the pulsatile pressure signal.
The heart was exposed through a thoracotomy at the left fifth intercostal space. The pericardial sac was opened, and a pericardial cradle was created. Left ventricular pressure was measured by means of a pressure transducer cannula (Mikro-tip, model MPC 500, Millar Instruments, Inc., Houston, Tex.) inserted into the left ventricular chamber through an apical stab wound. The first derivative of the left ventricular pressure was derived by electronically differentiating the pressure signal. Heart rate was obtained by triggering a pressure processor amplifier (model 13-4615-52, Gould) with the left ventricular pressure signal.
The coronary thrombosis model used in this study was implemented according to the procedure first described by Gold et al16 and later modified by the same group to include a distal high-grade coronary stenosis.17 A 2-cm segment of the proximal left anterior descending coronary artery (LAD) was isolated. All minor branches of the artery were ligated. A cannula (PE-20) was inserted into one of the branches located in the midportion of the isolated segment. The arterial segment was instrumented from the distal to the proximal end with a plastic screw clamp, a ligature snare, the side-branch cannula, a second ligature snare, and a transit time ultrasonic flow probe (model 2RB probe, model T201 meter, Transonic Systems, Inc., Ithaca, N.Y.). A recording electrode was implanted in the subendocardium of the left ventricular region perfused by the distal LAD for monitoring the ST segment on the electrogram.
Left ventricular pressure and its first derivative, LAD flow, arterial pressure, and the electrogram signals were displayed on a strip-chart recorder (model 3800, Gould). Instantaneous heart rate was monitored on a digital display (model 53-G2682-09, Gould).
Lidocaine was infused prophylactically (0.1 mg/kg per minute intravenously) for the duration of the study to minimize arrhythmias consequent to LAD occlusion and reperfusion. After stabilization of hemodynamic, respiratory, and metabolic parameters, a baseline LAD flow was recorded. By adjusting the screw clamp, LAD flow was reduced to =40% of baseline flow. Developers of this model have determined angiographically that this degree of flow restriction yields a >90% reduction in the luminal diameter. 17 To promote thrombus adherence to the vessel wall, the endothelium of the LAD in the region between the ligature snares was traumatized by four or five compressions of the artery with a hemostat. Both ligature snares were closed to form a blind sac. An occlusive thrombus was formed by injecting a mixture of fresh autologous whole blood (0.3 ml) and thrombin (10-40 units) into the isolated LAD via the cannulated side branch. Five minutes and 8 minutes later, the proximal and distal ligature snares, respectively, were released.
Experimental Protocol
The experimental protocol ( Figure 1 ) was initiated after allowing the occlusive thrombus to age for at least 30 minutes. Adjunctive drug therapy was then administered and continued for the duration of the protocol (Figure 1 ). Drugs consisted of either 0.9% saline control, one of three doses of HI (0.3 mg/kg followed by 0.3 mg/kg per hour, 1 mg/kg followed by 1 mg/kg per hour, or 2 mg/kg followed by 2 mg/kg per hour), or one of two doses of HE (60 units/kg followed by 40 units/kg per hour or 100 units/kg followed by 60 units/kg per hour). Fifteen minutes after beginning adjunctive drug infusion, streptokinase (750,000 IU) was initiated and infused over the ensuing 60 minutes (Figure 1 ).
Vessel patency was monitored for 180 minutes after streptokinase infusion with the flow probe on the LAD. "Reperfusion" after thrombolysis was defined as a return of LAD flow to .50% of the baseline (after stenosis) flow for a period of at least 5 minutes. A subsequent vessel "reocclusion" was documented when flow persisted at <50% of baseline for at least 5 minutes. Because some dogs exhibited cyclical flow variations, subsequent reperfusion/reocclusion patterns were defined by the same criteria as the original reperfusion/reocclusion. Parameters evaluated within each FIGURE 1. Schematic representation of experimental protocol. After stabilizing the animal and initiating lidocaine infusion, the coronary thrombus was formed and allowed to age for 30 minutes. Adjunctive drug therapy (or saline) was initiated and continued for the remainder of the protocol. Fifteen minutes later, streptokinase was infused over a period of 1 hour. Left anterior coronary arterial flow was monitored for 3 hours after initiating streptokinase. Hemodynamic parameters and buccal mucosa bleeding times (BMBTs) were measured, and blood samples were withdrawn for determining activated partial thromboplastin times (APTTs) and prothrombin times (PTs) at various times throughout the protocol as indicated. treatment group were 1) time to reperfusion (i.e., time after initiating streptokinase until documented reperfusion, only for vessels that were recanalized), 2) incidence of reperfusion, 3) time to reocclusion (i.e., time from a documented reperfusion until a documented reocclusion, only for vessels that reoccluded), 4) incidence of reocclusion, 5) duration of initial reperfusion (i.e., time from a documented reperfusion until either a documented reocclusion or experiment terminus, for all vessels that were reperfused), and 6) total duration of reperfusion (summation of the time in which LAD flow was .50% of baseline independent of the duration of reflow, only for vessels with documented reperfusion).
Hemodynamic parameters (left ventricular pressure [systolic and end diastolic] and its first derivative, mean arterial pressure, and heart rate) were measured before thrombus formation (after stenosis), before and 15 minutes after initiating adjunctive drug therapy, and at 30, 60, 120, and 180 minutes after initiating streptokinase infusion (Figure 1) .
Arterial blood samples ( Figure 1) Figure 2 displays the times of documented reperfusion for each of the eight dogs within each drug regimen. There was no reperfusion in any of the salinetreated dogs, so these data are excluded from the figure. Streptokinase was initiated at time 0 and continued for 60 minutes. Each horizontal line depicts a time period in which reflow exceeded 50% of the baseline (poststenotic) flow. The data indicate a dose-dependent enhancement of reperfusion within each agent and an overall superior effect of HI over HE at the doses tested. 12% (1/8) 59 (1) 10 (1) 34 (1) 100% (1/1) 10 (1) HE 100 75% (6/8) 65±16 (6) 46±13 (6) 53±11 (6) 83% (5/6) 40±14 (5) HI, hirudin; HE, heparin; HI 0.3; 0.3 mg/kg followed by 0.3 mg/kg per hour; HI 1, 1 mg/kg followed by 1 mg/kg per hour; HI 2, 2 mg/kg followed by 2 mg/kg per hour; HE 60, 60 units/kg followed by 40 The various reperfusion/reocclusion parameters from the individual experiments in Figure 2 are summarized in Table 1 . Numbers in parentheses indicate the number of animals corresponding to each data value. There was a dose-dependent increase in the incidence of reperfusion for both HI and HE when administered as adjuncts to streptokinase. The high and medium doses of HI resulted in 100% and 75% incidences of reperfusion, respectively. These values were not significantly different from the results with the high dose of HE (75%) but were statistically greater than those with the low dose of HE. At this dose of HE, only one of the eight dogs experienced coronary recanalization with streptokinase.
Although the incidence of reocclusion decreased from 50% to 33% with the first two doses of HI, there was no additional benefit with the highest dose. Likewise, the duration of the initial reperfusion period and the total time of reperfusion doubled from the low to medium dose of HI but did not increase further with the highest dose. With HE, the incidence of reocclusion was high (100% and 83%) with either dose. Although the incidence of reocclusion tended to be lower with HI than with HE, this difference did not reach statistical significance, probably because of the low number of animals exhibiting reperfusion within some of the groups (e.g., the HE group infused with 60 units/kg followed by 40 units/kg per hour).
Comparison of the two groups indicates that the time to reperfusion was reduced, and the duration of the initial reperfusion was prolonged in the high-dose HI group to a greater extent than the corresponding parameters in the high-dose HE group. Likewise, with respect to the same two parameters, the medium dose of HI was superior to the low dose of HE. Thus, whereas the highest dose of HI yielded a rapid (33 minutes) and sustained (106 minutes) recanalization after streptokinase, vessels treated with the high dose of HE experienced only a brief period of reflow (46 minutes) after a delayed onset of 65 minutes.
APTT and PT were measured throughout the experimental protocol as an index of the degree of anticoagulation. APTT and PT (both as a multiple of control) versus time for each drug regimen are displayed in Figure 3 . Both agents caused a dose-dependent increase in each coagulation time. After an initial peak, each parameter quickly reached a steady state and was maintained throughout the duration of the protocol. Table 2 depicts the control (in seconds) and change (as a multiple of control) in the APTT, PT, and the BMBT for the six groups. There were no differences in baseline APTT, PT, or BMBT between the six groups ( Table 2) . APTT and PT were unchanged in the salinetreated dogs (Table 2 ). APTT and PT increased significantly in a dose-dependent fashion within the HI and HE groups. Differences between groups are indicated in the table. Briefly, the high dose of HE prolonged APTT significantly greater than did each dose of HI, whereas the response to the low dose of HE exceeded that of only the low dose of HI. Although BMBTs increased by 20-30% in the saline and five drug groups, these changes were not significantly different between the six groups.
Comparison of the change in APTT versus the total reperfusion time or versus residual thrombus mass for the HI and HE groups reflected dramatically different anticoagulant/antithrombosis profiles for the two agents ( Figure 4 ). Whereas nearly maximal reperfusion (180 minutes minus a finite time for the onset of reperfusion) occurred with HI at an APTT increase in the low therapeutic range (1.5-2.0), the threshold for reperfusion in the HE group was at an APTT increase of 1.8 times control. Likewise, all of the HE-treated dogs that exhibited significant recanalization had APTT increases outside the therapeutic range (i.e., >2.5 times control). Linear regression analysis was applied to the APTT versus total reperfusion time relations for the combined data within the HI and HE groups (Figure 4, top panel) .
The resulting estimated slopes were 92 and 20 for the HI and HE data, respectively. These slopes were statistically different, as indicated by the significant interaction effect from analysis of covariance.
Likewise, there was a significantly greater reduction in residual thrombus mass with HI than with HE for similar degrees of anticoagulation (i.e., increase in APTT) (Figure 4, bottom panel) . Thus, each group exhibited drug-and dose-dependent decreases in residual thrombus mass that were coincident with the incidence of vessel recanalization ( Figure 5 ). In the saline- Table 2 .
Hemodynamic parameters at various times throughout the protocol for the six groups of dogs are displayed in Table 3 . Changes were minor in all cases except for left ventricular dP/dt, which decreased by 25-30% in all six groups by the final 1-2 hours of the protocol. Thus, there appear to be either no substantial hemodynamic changes or consistent drug-independent hemodynamic changes between groups.
Discussion
Thrombin plays a key role in the bioregulation of hemostasis and thrombosis. As the final common mediator of the intrinsic and extrinsic coagulation pathways, thrombin proteolytically cleaves fibrinogen to form the fibrin monomer. Feedback activation of factors V and VIII by thrombin amplifies its own generation by producing prothrombinase complexes that then cleave prothrombin to yield additional thrombin. Fibrin polymerization forms a matrix that is stabilized by thrombin's activation of factor XIII. This stabilization process renders the clot insoluble and increases its resistance to subsequent fibrinolysis. However, clot dissolution itself can enhance thrombin generation by platelet-dependent mechanisms or by releasing enzymatically active thrombin bound to fibrin within the clot. Hirudin FIGURE 5. Individual and mean residual thrombus masses from saline-, hirudin-, and heparintreated dogs. Hirudin was administered at 0.3 mg/kg followed by 0.3 mg/kgper hour, 1 mg/kgfollowed by 1 mg/kg per hour, and 2 mg/kg followed by 2 mg/kg per hour; heparin was administered at 60 units/kg followed by 40 units/kg per hour and 100 units/kg followed by 60 units/kg per hour. Open and closed symbols indicate vessels that did and did not reperfuse, respectively, after streptokinase administration. There was a dose-dependent decrease in thrombus mass with both hirudin and heparin when compared with thrombi from the saline-treated HI was also an order of magnitude more effective than HE in reducing residual thrombus mass at a comparable therapeutic level of anticoagulation (Figure 4 , bottom panel). In addition, for a given residual thrombus mass there was a greater degree of reperfusion in the HI-than in the HE-treated vessels. This is evident from the results in Figure 5 in which no reperfusion occurred in vessels from either treatment group with thrombus masses abovẽ 8-9 mg. All of the vessels in the HI group with thrombus masses below this apparent reperfusion threshold exhibited significant reflow (open circles in Figure 5 ). On the contrary, :''40O% of the HE-treated vessels with thrombi below this level remained resistant to recanalization by streptokinase. Also, of those that did exhibit reperfusion, the total reperfusion time was short because of the high incidence of reocclusion or cyclic flow variations in the HE groups. These observations suggest that other factors, in addition to the absolute reduction in thrombus mass, may interact to determine reflow in these vessels. For example, HE may directly stimulate platelets and increase local platelet production of thromboxane A2, whereas HI has been demonstrated to inhibit platelets and the release of potent vasoconstrictor agents. [46] [47] [48] 60, 61 This may be of added importance during t-PA or streptokinase therapy in which HE, but not HI, prevents the reduced platelet aggregatory response to plasmin generation.6263 Thus, adjunctive thrombolytic treatment with HE may promote vasospastic events and thereby elevate the threshold for functional recanalization by further constricting the underlying stenosis.k4,65
Collectively, our findings are consistent with clinical observations that an unacceptable percentage of patients treated with HE at therapeutic levels of anticoagulation remain resistant to coronary clot dissolution by fibrinolytics or experience an undesirably high incidence of subsequent reocclusion.2627 Our results with streptokinase combined with the favorable results by others with t-PA in various animal models suggest that HI at moderate levels of anticoagulation should exhibit a clear adjunctive thrombolytic advantage over HE in patients treated for acute myocardial infarction.
Hirudin is well tolerated clinically and in laboratory animals. [66] [67] [68] [69] In dogs, acute administration of 10 mg/kg hirudin (five times our highest dose) caused no hemodynamic effects.68 Template bleeding times in humans are not significantly prolonged after therapeutic intravenous doses of hirudin.38,69 Likewise, in various animal models, bleeding complications are detected only at relatively high doses of hirudin that are at least an order of magnitude greater than the doses required for significant antithrombosis.70,71 When administered in conjunction with streptokinase (present study) or t-PA,11 HI (i.e., CGP 39393) also does not significantly prolong template bleeding times in dogs. Recent studies have revealed that the prolongation of template bleeding time is a reliable predictor of hemorrhagic diathesis occurring in animals and patients treated with t-PA and aspirin.72,73 Therefore, HI, in contrast to specific antiplatelet agents,11,55,74 appears to provide a high degree of antithrombosis without impeding primary hemostasis and predisposing the recipient to bleeding complications. Hirudin also appears to be a weak immunogen, indicating that repeat exposures to the agent are unlikely to elicit immune reactions or to compromise its 
